Norwegian biotech company Oncoinvent ASA (OSE:ONCIN) on Tuesday reported favourable safety and tolerability results from the first interim safety analysis of its randomised phase 2 trial evaluating Radspherin in patients with advanced ovarian cancer and peritoneal metastases.
As of 30 October 2026, 74 patients had been randomised, with 56 primary ovarian cancer patients included in the safety analysis. Of these, 40 received a single 7 MBq intraperitoneal dose of Radspherin following surgery alongside standard care, while 16 received standard care alone.
No serious adverse events were considered related to Radspherin, and no deaths or adverse events leading to treatment discontinuation were reported. The incidence of treatment-emergent adverse events was similar across both groups, with most events in the Radspherin arm considered unrelated to treatment.
The Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November 2026 and recommended that the trial continue without modifications.
Recruitment is expected to be completed in the first half of 2027, with the interim efficacy results scheduled for April 2027 and expected to include close to all randomised patients.
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Akeso publishes ivonescimab Phase II study results in Nature Medicine
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma